by healthadvances Posted on May 16, 2023 Winning the China Market: A Review of NRDL Inclusions Read More
by healthadvances Posted on July 14, 2022 Impact of Innovation on Market Access for Wound Care Products Read More
by healthadvances Posted on February 28, 2020April 13, 2020 Overcoming Challenges to Realize the Promise of Genetic Medicine Read More
by healthadvances Posted on April 16, 2019April 13, 2020 Better Market Access in China – Government Improves Pricing and Reimbursement Environment Read More
by healthadvances Posted on April 7, 2019April 13, 2020 Keytruda, a case study for the improved regulatory environment in China Read More
by healthadvances Posted on March 27, 2019April 13, 2020 Improvements in China Drug Registration – Opening the Door to the China Market for Global BioPharma Read More
by healthadvances Posted on November 9, 2018April 13, 2020 Health Advances Presentation at ISPOR: An Initial Analysis of the Cost-Based Pricing Revisions in Japan Read More
by healthadvances Posted on November 9, 2018April 13, 2020 Health Advances Presentation at ISPOR: Findings from the First Five Years of the NICE HST Program for Ultra Rare Conditions Read More
by healthadvances Posted on September 18, 2018April 13, 2020 New Assessment Pathway for Invasive High-Risk Medical Devices in Germany: Balancing Market Access, Evidence and Patient Benefit Read More
by healthadvances Posted on August 23, 2018April 13, 2020 Disease Management Programs (DMPs) in Germany: The Importance of Guideline Inclusion for Chronic Therapies Read More
by healthadvances Posted on June 25, 2015April 15, 2020 Drug Pricing & Reimbursement at the Boston CMO Network Read More
by healthadvances Posted on June 22, 2015April 15, 2020 Pricing Orphan and Specialty Drugs-Insights from the World Orphan Drug Congress & ISPOR Read More
